Tag Archives: Mayank Mamtani

Intercept Pharma (ICPT) Receives a Buy from B.Riley FBR

In a report released yesterday, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Intercept Pharma (ICPT – Research Report). The company’s shares closed yesterday at $117.34. Mamtani commented: “Sciences, Inc. announced negative results from their Ph. III STELLAR-4

B.Riley FBR Remains a Buy on Arrowhead Research (ARWR)

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Arrowhead Research (ARWR – Research Report) today and set a price target of $19. The company’s shares closed on Friday at $15.66. Mamtani said: “Inc (ARWR) reported fiscal 1Q19 (calendar